Insider Investment: Patrick Delong Picked up 750 Shares of Crimson Wine Group Ltd; Palo Alto Investors Boosted Its Sage Therapeutics (SAGE) Holding

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Palo Alto Investors Llc increased Sage Therapeutics Inc (SAGE) stake by 2.99% reported in 2017Q4 SEC filing. Palo Alto Investors Llc acquired 23,555 shares as Sage Therapeutics Inc (SAGE)’s stock declined 6.84%. The Palo Alto Investors Llc holds 810,806 shares with $133.55M value, up from 787,251 last quarter. Sage Therapeutics Inc now has $8.16 billion valuation. The stock increased 0.93% or $1.61 during the last trading session, reaching $175.33. About 466,341 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 17, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Since December 14, 2017, it had 0 insider purchases, and 6 insider sales for $42.42 million activity. $9.96 million worth of stock was sold by STARR KEVIN P on Tuesday, April 17. $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by Robichaud Albert. Another trade for 58,139 shares valued at $10.00M was made by PAUL STEVEN M on Tuesday, March 6. Another trade for 44,000 shares valued at $7.80 million was made by Kanes Stephen on Wednesday, January 10. The insider FRATES JAMES M sold 7,000 shares worth $1.08M. Another trade for 28,153 shares valued at $4.02 million was sold by IGUCHI KIMI.

Investors sentiment increased to 1.49 in 2017 Q4. Its up 0.28, from 1.21 in 2017Q3. It increased, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Moreover, Rmb Capital Mgmt Limited Liability has 0.11% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 26,347 shares. 17,200 are held by Sectoral Asset Mngmt. State Street accumulated 0.01% or 1.12M shares. California State Teachers Retirement Sys owns 59,635 shares. Price T Rowe Assoc Md has 6.31M shares for 0.17% of their portfolio. Hbk Investments Lp has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). The Switzerland-based Jabre Ptnrs has invested 0.06% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Citadel Advsr Ltd Llc owns 36,951 shares. Renaissance Technologies Ltd Company owns 22,931 shares. Cwm Ltd Company holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 6 shares. 5,147 were reported by Amalgamated Financial Bank. Ameritas Investment Prtn Inc has invested 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Boothbay Fund Management Limited Co reported 3,908 shares or 0.09% of all its holdings. 1,437 were accumulated by Ww Asset Mgmt Inc. First Republic Inv Management holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 2,942 shares.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: which released: “Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today” on April 20, 2018, also with their article: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on May 03, 2018, published: “Sage Therapeutics 2018 Q1 – Results – Earnings Call Slides” on May 03, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: and their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018 as well as‘s news article titled: “Sage Therapeutics asks FDA to approve lead drug for postpartum depression” with publication date: April 23, 2018.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics has $277.0 highest and $18 lowest target. $141.44’s average target is -19.33% below currents $175.33 stock price. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. On Thursday, November 9 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Leerink Swann on Tuesday, September 12. The firm earned “Outperform” rating on Friday, November 17 by BMO Capital Markets. Raymond James upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, December 14 to “Strong Buy” rating. The stock has “Buy” rating by Chardan Capital Markets on Friday, November 10. Canaccord Genuity maintained the shares of SAGE in report on Monday, November 13 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Thursday, October 26. The rating was maintained by Bank of America with “Buy” on Thursday, November 16. The rating was maintained by Cowen & Co with “Buy” on Tuesday, September 12. The firm earned “Buy” rating on Tuesday, June 20 by Leerink Swann.

Patrick Delong, an insider and also President & CEO of the big company Crimson Wine Group Ltd made a purchase. He picked up 750 shares of the company with the insider buying transaction having a market value of $6,873 U.S Dollars – based on an average weighted cost of $9.2 for every share. Patrick Delong now indirectly has 0 shares. He also directly has 14039 shares. In total he holds a stake of 0.06%. A document available for public review here shows this insider activity, that was performed on May 16, 2018 and was filed with the Washington-based Security and Exchange Commission.

It closed at $9.15 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Crimson Wine Group, Ltd., through its subsidiaries, engages in the production and sale of ultra-premium and wines. The company has market cap of $219.58 million. The firm operates through two divisions, Wholesale and Direct to Consumer. It has a 35.47 P/E ratio. The firm sells wines through independent wine and spirit distributors in the United States; and independent importers and brokers internationally.

Investors sentiment decreased to 0.57 in 2017 Q4. Its down 0.68, from 1.25 in 2017Q3. It dropped, as 3 investors sold Crimson Wine Group, Ltd. shares while 4 reduced holdings. 2 funds opened positions while 2 raised stakes. 5.25 million shares or 0.64% less from 5.28 million shares in 2017Q3 were reported. Lawson Kroeker Inv Management Ne accumulated 360,955 shares. Karpas Strategies Ltd Limited Liability Company invested 0.07% of its portfolio in Crimson Wine Group, Ltd. (OTCMKTS:CWGL). Gilder Gagnon Howe And Limited Liability Company owns 20,524 shares or 0% of their US portfolio. Markston International Limited Liability Company reported 40 shares. Mutual Of America Cap Mgmt Ltd Co stated it has 0.11% in Crimson Wine Group, Ltd. (OTCMKTS:CWGL). Inr Advisory Ltd Liability Corp reported 10 shares. Price Michael F reported 969,200 shares. 200 are owned by Vigilant Cap Ltd Liability Corporation. 60 were accumulated by Highlander Capital Ltd Liability Com. Beck Mack & Oliver Limited Liability has invested 1.11% in Crimson Wine Group, Ltd. (OTCMKTS:CWGL). Staley Capital Advisers accumulated 29,546 shares. 70 are held by Edge Wealth Mgmt Ltd Liability. 12,203 were reported by Menlo Advisors Ltd Liability. Panagora Asset Mngmt stated it has 1,185 shares or 0% of all its holdings.

Since March 19, 2018, it had 14 buys, and 0 insider sales for $212,255 activity. STEINBERG JOSEPH S had bought 1,000 shares worth $9,500. 2,372 shares valued at $23,103 were bought by Cumming John D. on Monday, March 26. DeLong Patrick M also bought $4,840 worth of Crimson Wine Group, Ltd. (OTCMKTS:CWGL) shares.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart